New Heart Disease Study Findings Have Been Reported from University of Macau (Clinical and Economic Evaluation of Salvianolate Injection for Coronary Heart Disease: A Retrospective Study Based on National Health Insurance Data in China)

2020 JUL 06 (NewsRx) -- By a News Reporter-Staff News Editor at Heart Disease Daily -- Fresh data on heart disease are presented in a new report. According to news reporting from the University of Macau by NewsRx journalists, research stated, “ObjectiveThe study aimed to conduct clinical and economic evaluation of salvianolate injection for patients with coronary heart disease (CHD) in comparison to Danhong injection and alprostadil injection.MethodThis was a retrospective study using National Health Insurance Data about inpatients diagnosed with CHD in China in 2015 who met the inclusion criteria. The recruited patients were divided into two samples: surgery and non-surgery.”

The news editors obtained a quote from the research from University of Macau: “The exposed group received salvianolate injection, while the control group received either alprostadil injection or Danhong injection. The medical cost per hospitalization, hospitalization duration, and the rehospitalization rates were used as outcome indicators. Heterogeneity was processed according to disease stratification. Propensity score matching and multivariate analysis were used for statistical analysis to control potential confounding factors.ResultsThe hospitalization duration of salvianolate injection group was significantly (P < 0.05) shorter than that of Danhong injection group in the non-surgery sample. The hospitalization duration of salvianolate injection group was significantly (P < 0.05) shorter than those of alprostadil injection group in both surgery and non-surgery samples. In the non-surgery sample, the medical cost per hospitalization of salvianolate injection group was significantly (P < 0.05) lower than that of alprostadil injection group. However, there were no statistical differences of rehospitalization rates in salvianolate injection group versus alprostadil injection group or salvianolate injection group versus Danhong injection group in both surgery and non-surgery samples.”

According to the news editors, the research concluded: “Salvianolate injection showed advantages in reducing hospitalization duration for inpatients with CHD when comparing with alprostadil injection and Danhong injection. The results of this real-world study can help to inform clinical practice for CHD patients.”

For more information on this research see: Clinical and Economic Evaluation of Salvianolate Injection for Coronary Heart Disease: A Retrospective Study Based on National Health Insurance Data in China. Frontiers in Pharmacology, 2020,11. (Frontiers in Pharmacology - http://journal.frontiersin.org/journal/pharmacology). The publisher for Frontiers in Pharmacology is Frontiers Media S.A.

A free version of this journal article is available at https://doi.org/10.3389/fphar.2020.00887.

Our news journalists report that additional information may be obtained by contacting Lisong Yang, State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, Macau. Additional authors for this research include Xiaolan Chen, Carolina Oi Lam Ung, He Zhu, Hao Hu, Sheng Han.

(Our reports deliver fact-based news of research and discoveries from around the world.)